Nearly half of all breast cancer survivors will develop lymphedema in their lifetime, and there are currently 4 million lymphedema patients in the US. Lymphedema is limb swelling disease that is debilitating both physically and psychologically, as the disease causes pain, depression, and overall reduced quality of life. The disease also results in significant costs – roughly $7-12 thousand in additional healthcare spending annually per patient. It is estimated that the direct cost of treating lymphedema is $4 billion annually for all patients in the United States, and associated indirect healthcare costs exceed $40 billion annually. The biggest problem with lymphedema is that the current standard of care does not detect the disease until an average of 10-20% swelling, which is well beyond the therapeutic window and leaves patients with permanent lymphedema. Ultimately, patients are being diagnosed with lymphedema too late. Doctors and therapists are actively looking for a new technology to improve the standard of care and monitoring for lymphedema.
LymphaTech has developed a new technology from that aims to enhance the standard of diagnosis of lymphedema with a novel 3D imaging platform for clinical and home-health monitoring of the disease. Our device will provide value to the entire lymphedema value chain by possessing a unique combination of three critical features: 1) it will produce accurate volume and circumference measurements to track swelling progression and allow for precise fitting of compression garments, 2) it will be cost-effective and affordable for the majority of lymphedema clinics, and 3) finally, and most importantly, it will be designed so patients can use the scanner at home to monitor themselves routinely between their regularly scheduled clinic visits.
Our team has research expertise in lymphatic physiology, biomechanics, and diagnostics, and a combined 11 years of industry experience in finance, valuation, information technology, operations, and engineering. LymphaTech’s founders have all seen the impact lymphedema has had on someone close to them, and are passionate about improving the standard of care for patients.